+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID05898399

Evaluation of Oral ART6043 Alone and Combined with Olaparib in Patients With Advanced or Metastatic Solid Tumors Including Breast Cancer

Led by Artios Pharma Ltd · Updated on 2026-10-19

181

Participants Needed

27

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating ART6043, an oral anti-cancer drug, alone or combined with the PARP inhibitor olaparib, in patients with advanced or metastatic solid tumors. The study focuses on cancers with DNA repair defects and includes patients with specific genetic mutations like germline BRCA in advanced breast cancer. The trial aims to assess safety, tolerability, pharmacokinetics, and preliminary effectiveness of ART6043. The study has two parts Part A includes dose escalation of ART6043 alone Part A1 and in combination with olaparib Part A2 for advanced cancers with DNA damage response gene defects. Part B is a dose-expansion phase comparing ART6043 plus olaparib against olaparib alone in patients with HER2-negative advanced breast cancer and germline BRCA mutations. Treatments are administered in 21-day cycles, and patients may continue therapy as long as clinical benefit is observed or until progression or unacceptable toxicity. Participants will undergo regular assessments including monitoring for dose limiting toxicities during the first treatment cycle and progression-free survival over up to 3.7 years. Evaluations include adverse events, tumor response, changes in tumor size and cancer markers, pharmacokinetics, and overall survival. Safety is monitored throughout, with follow-up visits after treatment discontinuation. The total study duration may extend until disease progression or other stopping criteria are met.

CONDITIONS

Brief Title

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

Research Team

A

Artios Pharma

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here